Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Subscribe To Our Newsletter & Stay Updated
